Philip Morris beats Q1 forecast but U.S. nicotine pouch shipments drop sharply

What happened

Philip Morris International posted adjusted earnings of $1.96 per share in the first quarter, surpassing the $1.83 analyst consensus. Revenue climbed 9.1% to $10.15 billion, above the expected $9.91 billion. The company's smoke-free product segment, which now represents 43% of total revenue, grew 12.4% overall. Internationally, smoke-free revenue jumped 25%, with the IQOS heated tobacco device overtaking Marlboro as the top nicotine brand in markets where it's available. The combustibles business also contributed, with revenue up 6.7% on higher pricing despite lower volumes. Philip Morris issued full-year adjusted earnings guidance of $8.36 to $8.51 per share, assuming 5% to 7% organic revenue growth.

Why the stock moved

Shares rose 2.8% in premarket trading following the earnings beat and solid international performance. However, the company faces challenges in the U.S. market, where total volumes, revenue, and profit all declined. Shipments of Zyn nicotine pouches—a key growth product—fell nearly 24% in the quarter, even as industry data shows rising consumer demand for the product. This disconnect suggests supply constraints or competitive pressures that could weigh on near-term domestic growth. Philip Morris said it is investing more heavily in Zyn to expand flavor options and improve its competitive position.

Bigger picture

Philip Morris is in the midst of a multi-year transition away from traditional cigarettes toward smoke-free alternatives like IQOS and Zyn. Internationally, this strategy is paying off, with IQOS now outpacing Marlboro in key markets. In the U.S., however, the picture is more complicated. The sharp drop in Zyn shipments despite strong underlying demand raises questions about the company's ability to capitalize on the fast-growing nicotine pouch category at home. The company also noted minor headwinds from the Iran conflict, which affected global travel retail and drove up energy and transport costs, though it does not expect prolonged impact.

What investors watch

Investors will monitor whether Philip Morris can close the gap between Zyn consumer demand and actual shipment volumes in upcoming quarters. Any updates on production capacity, distribution agreements, or competitive dynamics in the U.S. nicotine pouch market will be critical. Internationally, the pace of IQOS adoption and the company's ability to sustain double-digit growth in smoke-free products remain key. Guidance assumes modest revenue growth of 5% to 7%, so any changes to that outlook—particularly around U.S. performance or geopolitical risks—could move the stock.

This article was generated by Quantli AI using publicly available news sources.